Efficacy and safety of off-label use of rituximab in refractory lupus: Data from the Italian Multicentre Registry

Clinical and Experimental Rheumatology

Volumn 33, Issue 4, 2015, Pages 449-456

  Iaccarino, Luca ^a   Bartoloni, Elena ^b   Carli, Linda ^c   Ceccarelli, Fulvia ^d   Conti, Fabrizio ^d   De Vita, Salvatore ^e   Ferraccioli, Gianfranco ^f   Galeazzi, Mauro ^g   Gatto, Mariele ^a   Gerli, Roberto ^b   Govoni, Marcello ^h   Gremese, Elisa ^f   Iuliano, Annamaria ^g   Mansutti, Elena ^e   Moroni, Gabriella ⁱ   Mosca, Marta ^c   Nalli, Cecilia ^j   Naretto, Carla ^k   Padovan, Melissa ^h   Palma, Lavinia ^a   Raffiotta, Francesca ⁱ   Roccatello, Dario ^k   Tincani, Angela ^j   Valesini, Guido ^d   Zen, Margherita ^a   Doria, Andrea ^a   more..

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^f CATHOLIC UNIVERSITY   (Italy)

^g UNIVERSITY HOSPITAL OF SIENA   (Italy)

^h UNIVERSITY OF FERRARA   (Italy)

ⁱ FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^j UNIVERSITY OF BRESCIA   (Italy)

^k UNIVERSITY OF TURIN   (Italy)

more..

Author keywords

Complete response; Italian registry; Lupus activity; Lupus nephritis; Rituximab; Systemic lupus erythematosus

Indexed keywords

RITUXIMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BRAIN INFECTION; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EUROPEAN CONSENSUS LUPUS ACTIVITY MEASUREMENT SCORE; FEMALE; FOLLOW UP; HUMAN; INFECTION; INFUSION RELATED REACTION; INTESTINE INFECTION; ITALY; KIDNEY FUNCTION; LUNG INFECTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RETREATMENT; SCORING SYSTEM; SEPSIS; SKIN INFECTION; TREATMENT DURATION; URINARY TRACT INFECTION; VIRUS REACTIVATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG MONITORING; DRUG RESISTANCE; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; OFF LABEL DRUG USE; PATHOPHYSIOLOGY; PROCEDURES; REMISSION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; DRUG RESISTANCE; FEMALE; HUMANS; IMMUNOSUPPRESSION; ITALY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; OFF-LABEL USE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84939521363     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. ZEN M, BASSI N, NALOTTO L et al.: Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study. Clin Exp Rheumatol 2012; 30: 856-63.
2. RAHMAN A, ISENBERG DA: Systemic lupus erythematosus. N Engl J Med 2008; 358: 929-39.
3. MOSCA M, TANI C, ARINGER M et al.: European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 2010; 69: 1269-74.
4. BERTSIAS G, IOANNIDIS JP, BOLETIS J et al.: Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008; 67: 195-205.
5. DORIA A, IACCARINO L, GHIRARDELLO A et al.: Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med 2006; 119: 700-6.
6. DORIA A, GATTO M, ZEN M, IACCARINO L, PUNZI L: Optimizing outcome in SLE: treating-to-target and definition of treatment goals. Autoimmun Rev 2014; 13: 770-7.
7. GATTO M, ZEN M, GHIRARDELLO A et al.: Emerging and critical issues in the pathogenesis of lupus. Autoimmun Rev 2013; 12: 523-6.
8. GATTO M, KISS E, NAPARSTEK Y, DORIA A: In-/off-label use of biologic therapy in systemic lupus erythematosus. BMC Med 2014 published on 17 February 2014. doi: 10.1186/1741-7015-12-30.
9. LU TY, NG KP, CAMBRIDGE G et al.: A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 2009; 61: 482-7.
10. RAMOS-CASALS M, SOTO MJ, CUADRADO MJ, KHAMASHTA MA: Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 2009; 18: 767-76.
11. TERRIER B, AMOURA Z, RAVAUD P et al.: Safety and efficacy of rituximab in systemic lupus erythematosus. Results from 136 patients from the French autoimmunity and rituximab registry. Arthritis Rheum 2010; 62: 2458-66.
12. WITT M, GRUNKE M, PROFT F et al.: German Registry of Autoimmune Diseases (GRAID) Investigators. Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE)-results from a nationwide cohort in Germany (GRAID). Lupus 2013; 22: 1142-9.
13. CONDON MB, ASHBY D, PEPPER RJ et al.: Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 2013; 72: 1280-6.
14. RAMOS-CASALS M, GARCíA-HERNáNDEZ FJ, de RAMóN E et al.: BIOGEAS Study Group. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol 2010; 28: 468-76.
15. DíAZ-LAGARES C, CROCA S, SANGLE S et al.: UK-BIOGEAS Registry. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev 2012; 11: 357-64.
16. ROVIN BH, FURIE R, LATINIS K et al.: LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012; 64: 1215-26.
17. MERRILL JT, NEUWELT CM, WALLACE DJ et al.: Efficacy and safety of rituximab in moderately-to severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62: 222-33.
18. TAN EM, COHEN AS, FRIES JF et al.: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
19. VITALI C, BENCIVELLI W, ISENBERG DA et al.: Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. Clin Exp Rheumatol 1992; 10: 541-7.
20. BERTSIAS GK, TEKTONIDOU M, AMOURA Z et al.: European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012; 71: 1771-82.
21. ROCCATELLO D, SCIASCIA S, ROSSI D et al.: Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy. Nephrol Dial Transplant 2011; 26: 3987-92.
22. ENGEL P, GóMEZ-PUERTA JA, RAMOS-CASALS M, LOZANO F, BOSCH X: Thera-peutic targeting of B cells for rheumatic autoimmune diseases. Pharmacol Rev 2011; 63: 127-56.
23. FERRI C, CACOUB P, MAZZARO C et al.: Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: Results of multicenter cohort study and review of the literature. Autoimmun Rev 2011; 11: 48-55.
24. NALOTTO L, IACCARINO L, ZEN M et al.: Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature. Immunol Res 2013; 56: 362-70.
25. WEIDENBUSCH M, ROMMELE C, SCHROTTLE A, ANDERS HJ: Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant 2013; 28: 106-11.
26. REDDY V, JAYNE D, CLOSE D, ISENBERG D: B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. Arthritis Res Ther 2013; 15 (Suppl. 1): S2.
27. FERNANDEZ-NEBRO A, de la FUENTE JM, CARRENO L et al.: Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: The LESIMAB study. Lupus 2011; 21: 1063-76.
28. HAHN BH, McMAHON MA, WILKINSON A et al.: American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res 2012; 64: 797-808.
29. ROMERO-DIAZ J, ISENBERG D, RAMSEY-GOLDMAN R: Measures of adult systemic lupus erythematosus. Arthritis Care Res 2011; 63: S37-S46.
30. ISENBERG DA: Rituximab-it was the best of times, it was the worst of times. Autoimmun Rev 2012; 11: 790-1.
31. SEGURO LPC, ROSARIO C, SHOENFELD Y: Long-term complications of past glucocorticoid use. Autoimmun Rev 2013; 12: 629-32.
32. LUIJTEN RKMAC, FRITSCH-STORK RD, BIJLSMA RWJ, DERKSEN RHWM: The use of glucocorticoids in Systemic Lupus Erythematosus. After 60 years still more an art than science. Autoimmun Rev 2013; 12: 617-28.
33. ZEN M, CANOVA M, CAMPANA C et al.: The kaleidoscope of glucorticoid effects on immune system. Autoimmun Rev 2011; 10: 305-10.